FORM 10-Q/A No. 1

                    SECURITIES AND EXCHANGE COMMISSION

                          WASHINGTON, D.C.  20549




                Quarterly Report under Section 13 or 15(d)
                  of the Securities Exchange Act of 1934

                   For the Quarter Ended March 31, 1999


             Commission File Number               000-20175

                             NYER MEDICAL GROUP, INC
          (Exact name of registrant as specified in its charter)


                   Florida                                01-0469607
        (State or other jurisdiction of                (I.R.S. Employer
        incorporation or organization)                 Identification No.)


           1292 Hammond Street, Bangor, Maine                04401
        (Address of principal executive offices)          (Zip Code)


                              (207) 942-5273
              (Registrant's telephone number, including area code)





Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding twelve months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.  Yes    X   .   No       .

As of May 21, 1999, there were outstanding, 3,407,093 shares of common
stock,par value $.0001 per share.






FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC.  000-20175        MARCH 31, 1999




                                     INDEX

                                     PART I

                             FINANCIAL INFORMATION


                                                                   Page No.

  Item 1.  Financial Statements:


           Consolidated Balance Sheets, March 31, 1999
                and December 31, 1998                                3-4


           Consolidated Statements of Operations, Three Months
                Ended March 31, 1999 and March 31, 1998               5



           Consolidated Statements of Cash Flows, Three Months
                Ended March 31, 1999 and March 31, 1998              6-7


           Notes to Consolidated Financial Statements                8-9


  Item 2.  Management's Discussion and Analysis of
                First Quarter 1999 Results                          10-16



                          PART II - OTHER INFORMATION

  Item 3.  Other Information                                         17


           Signatures                                                18














FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC   000-20175        MARCH 31, 1999

                  NYER MEDICAL GROUP, INC AND SUBSIDIARIES
                        CONSOLIDATED BALANCE SHEETS

                                    ASSETS
                                         (Unaudited)
                                          March 31,    December 31,
                                              1999         1998
Current assets:
  Cash and cash equivalents              $3,860,397    $ 4,136,988
  Accounts receivable, less
    allowance for doubtful accounts
    of $165,764 at March 31, 1999
    and $188,076 at December 31, 1998     2,882,054      3,560,377
  Inventories, net                        4,269,716      4,073,051
  Prepaid expenses                          109,974        105,045
  Receivables from related parties           46,203         48,139

            Total current assets         11,168,344     11,923,600

Property, plant and equipment, at
  cost:
  Land                                       92,800         92,800
  Building                                  641,508        641,508
  Leasehold improvements                    398,482        381,702
  Machinery and equipment                   252,717        223,807
  Transportation equipment                  291,513        260,285
  Office furniture, fixtures,
    and equipment                           810,333        805,748

                                          2,487,353      2,405,850
  Less accumulated depreciation
    and amortization                       (951,525)      (902,872)

                                          1,535,828      1,502,978
Goodwill and other deferred assets,
  net of accumulated amortization of
  $419,933 and $386,171 at March 31,
  1999 and December 31, 1998,
  respectively                              769,047        802,809
Advances due from related companies          35,253         34,488
Other                                       145,121        148,167

                                            949,421        985,464

            Total assets                $13,653,593    $14,412,042






     See accompanying notes to consolidated financial statements.

FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC   000-20175        MARCH 31, 1999

                  NYER MEDICAL GROUP, INC AND SUBSIDIARIES
                        CONSOLIDATED BALANCE SHEETS

                  LIABILITIES AND SHAREHOLDERS' EQUITY

                                         (Unaudited)
                                          March 31,    December 31,
                                              1999         1998

Current liabilities:
  Notes payable due related parties      $   120,000    $  120,000
  Current portion of long-term debt          431,132       236,669
  Accounts payable                         2,298,994     2,627,292
  Accrued payroll and related taxes          118,354       206,465
  Accrued expenses and other
    liabilities                              112,254       322,753

           Total current liabilities       3,080,734     3,513,179


Notes payable due related party,
  net of current portion                     502,820       522,820
Long-term debt, net of current
  portion                                    439,910       480,711
Minority interest                            716,030       744,357
Deferred credits                             107,609       118,109

Shareholders' equity:
  Class A Preferred stock, par value
    $.0001, Authorized, issued and
    outstanding: 2,000 shares                      1             1
  Class B Preferred stock, series 1,
    par value $.0001, Authorized:
    2,500,000; issued and outstanding:
    1,000 shares at March 31, 1999 and
    December 31, 1998
  Common stock, par value $.0001
    Authorized: 10,000,000 shares;
    issued: 3,407,093 at March 31, 1999
    and December 31, 1998                        341           341
   Additional paid-in capital             15,238,376    15,238,376
   Stock sale receivable                    (115,500)     (115,500)
   Treasury stock (11,000 shares at
    March 31, 1999 and
    December 31, 1998)                       (52,249)      (52,249)
   Accumulated deficit                    (6,264,479)   (6,038,103)

     Total shareholders' equity            8,806,490     9,032,866

            Total liabilities and
              shareholders' equity       $13,653,593   $14,412,042

     See accompanying notes to consolidated financial statements.
FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC   000-20175        MARCH 31, 1999

                  NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
                CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)

                                  March 31,      March 31,
                                    1999           1998

Net sales                        $9,454,434     $7,899,806

Cost and expenses:
  Cost of goods sold              7,630,129      6,195,379
  Selling and retail              1,377,738      1,313,309
  Warehouse and delivery             85,532         89,221
  Administrative                    713,063        617,400
                                  9,806,462      8,215,309

        Operating loss             (352,028)      (315,503)

Other income (expense):
  Interest expense                  (24,075)       (28,118)
  Interest income                    74,700         98,758
  Other                              46,700
        Total other income           97,325         70,640

         Loss before
         minority interest         (254,703)      (244,863)
 Minority interest                    28,327         27,105

     Loss from continuing
         operations before
         income taxes              (226,376)      (217,758)
       Income taxes                                (12,504)
     Loss from continuing
         operations
         after income taxes        (226,376)      (230,262)

Discontinued operations
     Loss from operations of
         discontinued
         subsidiary-
         Genetic Vectors                          (117,431)
     Net Loss                    $ (226,376)    $ (347,693)

  Basic and diluted loss per
   common share from continuing
    operations                   $     (.07)    $     (.07)
  Basic and diluted loss per common
    share from discontinued
    operations                                        (.03)
  Basic and diluted loss per
    common share                 $     (.07)    $     (.10)
Weighted average common shares
    outstanding                   3,403,101      3,407,093
     See accompanying notes to consolidated financial statements.
FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC   000-20175        MARCH 31, 1999

                  NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
                     CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (Unaudited)

                                  March 31,      March 31,
                                    1999           1998
  Cash flows from operating
      activities:
  Net loss                       $ (226,376)    $ (347,693)
  Adjustments to reconcile to net cash
      used in operating activities:
  Loss of unconsolidated
      subsidiary                                   117,431
  Depreciation and amortization      86,025         92,884
  Gain on disposal of property, plant
      and equipment                                  1,700
  Gain on sale of pharmacy          (25,000)
  Minority interest                 (28,327)       (27,105)
   Changes in certain working capital
      elements                     (184,543)      (546,771)
      Net cash flows used in
           operating activities    (378,221)      (709,554)

Cash flows from investing activities:
  Purchase of property, plant and
      equipment                     (82,962)       (56,995)
  Proceeds from sale of pharmacy     50,800
  Net change in advances due from
      related companies                (765)         2,287
  Decrease (increase) in other
      assets, net                       895        (24,555)
      Net cash used in investing
           activities               (32,032)       (79,263)

Cash flows from financing activities:
  Proceeds from issuance of
      long-term debt                200,000        106,424
  Payments of long-term debt        (46,338)       (46,453)
  Net (repayments to)proceeds from
      notes due related parties     (20,000)        (6,000)

      Net cash provided by
           financing activities     133,662         53,971
Net decrease in cash
      and cash equivalents         (276,591)      (734,846)
Cash and cash equivalents at
      beginning of period         4,136,988      4,497,010
Cash and cash equivalents at
      end of period              $3,860,397     $3,762,164



     See accompanying notes to consolidated financial statements.
FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC   000-20175        MARCH 31, 1999

                  NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (Unaudited)

                                  March 31,    March 31,
                                    1999         1998


Changes in certain working capital
     elements:
  Accounts receivable, net      $  678,323   $ (115,590)
  Inventories                     (222,465)    (229,847)
  Prepaid expenses                  (4,929)      (3,467)
  Receivables from related parties   1,936      (27,952)
  Decrease in deferred credits     (10,500)     (10,000)
  Accounts payable                (328,298)      38,019
  Accrued payroll and related
      taxes                        (88,111)     (21,669)
 Accrued expenses and other
      liabilities                 (210,499)    (176,265)
     Net change                 $ (184,543)  $ (546,771)





                                   Three Months Ended


                                  March 31,   March 31,
                                    1999        1998

Cash paid during the first
    three months:
     Interest                   $   19,144   $   26,101


















FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC   000-20175        MARCH 31, 1999
               NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

1.  The consolidated financial statements included herein have been
    prepared by the Company, without audit, pursuant to the rules and
    regulations of the Securities and Exchange Commission.  Certain
    information and footnote disclosures normally included in financial
    statements prepared in accordance with generally accepted accounting
    principals have been condensed or omitted pursuant to such rules and
    regulations, although the Company believes that the disclosures are
    adequate to make the information presented not to be misleading.  In
    the opinion of management, the amounts shown reflect all adjustments
    necessary to present fairly the financial position and results of
    operations for the periods presented.  All such adjustments are of a
    normal recurring nature.

    Basic and diluted loss per share of common stock has been determined
    by dividing net earnings by the weighted average number of shares of
    common stock outstanding.

    It is suggested that the financial statements be read in conjunction
    with the financial statements and notes thereto included in the
    Company's Form 10-K for the year ended December 31, 1998.

2.  Business Segments:

    The Company had four active business segments in 1999, and 1998:
(1)wholesale and retail sale of surgical, diabetic, medical equipment and
supplies, (2) nutritional supplies (3) wholesale and retail distribution of
equipment, supplies, and novelty items to emergency medical service, fire
departments, and police departments, and (4) retail pharmacy drug store chain.
Business segments are determined based on products or services offered for sale.

    Summary data for the quarter ended March 31, 1999 is as follows:

            Diabetic,
         Medical, and    Nutritional    EMT, Fire, Police  Pharmacy
        Surgical Supplies  Supplies    Equip and Supplies  Chain     Corporate
Net Sales    $1,660,241                   $2,096,329     $ 5,697,864
Operating
(loss)income    (19,757)   $(84,588)         (69,701)        (82,976)$  (95,006)
Total assets  2,720,611     401,979        2,000,177       5,001,220  3,529,606
Capital
Expenditures     31,788       2,275           17,669          31,230
Depreciation
and
amortization     17,057      14,242           18,987          34,485      1,254
Interest income  (4,655)                                     (11,713)   (58,332)
Interest
expense           8,652                          398          15,025








FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC.  000-20175        MARCH 31, 1999

                 NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)


2.  Business Segments, continued

    Summary data for the quarter ended March 31, 1999 is as follows: continued

              Consolidated
Net Sales     $9,454,434
Operating
(loss)income     (352,028)
Total assets   13,653,593
Capital
Expenditures       82,962
Depreciation
and
amortization       86,025
Interest income   (74,700)
Interest
expense            24,075

    Summary data for the quarter ended March 31, 1998 is as follows:

            Diabetic,
         Medical, and    Nutritional    EMT, Fire, Police  Pharmacy
        Surgical Supplies  Supplies    Equip and Supplies  Chain     Corporate
Net Sales    $1,580,175                   $1,296,386     $ 5,023,245
Operating
(loss)income    (19,462)  $(117,284)        (173,832)         69,817 $  (74,742)
Total assets  2,805,028     357,952        2,454,404       4,532,605  5,521,518
Capital
Expenditures      2,941                          419          53,635
Depreciation
and
amortization     24,445      12,946           17,195          37,608        690
Interest income  (1,617)                                     (13,103)   (84,038)
Interest
expense          12,981                          769          14,368
Income tax
expense                                                       12,504



              Consolidated
Net Sales     $ 7,899,806
Operating
(loss)income     (315,503)
Total assets   15,671,507
Capital
Expenditures       56,995
Depreciation
and
amortization       92,844
Interest income   (98,758)
Interest
expense            28,118
Income tax
expense            12,504



FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC.  000-20175        MARCH 31, 1999

                 NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

  Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE FIRST QUARTER RESULTS


  Results of Operations

Quarter Ended March 31, 1999 as compared to Quarter Ended March 31, 1998.

NET SALES. Total sales for the first quarter of 1999 increased 19.7% over the
first quarter of 1998 to $9,454,434, representing an increase of $1,554,628.

The following table shows sales by subsidiary for first quarter of 1999 and
1998:

                     March 31,        March 31,
Subsidiary             1999             1998    % increase (decrease)
Eaton               $5,697,864      $5,023,245        13.4%
Anton                  709,421         741,013        (4.3)
ADCO                 1,355,922       1,298,842         4.4
SCBA                     4,296           8,278       (48.1)
ADCO South             280,433         281,334           -
Conway               1,382,612         547,094       152.7
Nyer Diabetic           23,886                       100.0
                    $9,454,434      $7,899,806

     The major reason for the increase in sales was due to Conway's
three fire truck deliveries in the first quarter of 1999 as compared
to no fire truck deliveries in the first quarter of 1998.  Eaton's
increase was due to the acquisition of two pharmacies in the first
quarter of 1998.


GROSS PROFIT MARGIN.  The Company's overall gross margins were approximately
19.3% in 1999 as compared 21.6% for the first quarter of 1998.

The following is a table of gross margins by subsidiary for the first
quarter of 1999 and 1998:

               March 31,        March 31,
Subsidiary        1999             1998
Eaton             20.2%            21.8%
Anton             19.6             14.6
ADCO              24.8             24.6
SCBA              41.2             61.6
ADCO South        29.1             24.4
Conway             8.1             14.5
Nyer Diabetic     19.1                -




FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC.  000-20175        MARCH 31, 1999

                 NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

  Results of Operations: continued,

     Eaton's gross margin declined due to lower reimbursements from insurance
companies, medicare and medicaid.  They believe they can off set this decline
by increased sales volume.  Anton's increase was the result of higher
supplies sales and lower sales in equipment sales (supplies sales generally
have a higher gross profit margin than equipment sales).  Conway's decrease
in margin was the result of three fire truck deliveries in the first quarter
of 1999 as compared to no fire truck deliveries in the first quarter of 1998.
Fire trucks and equipment sales are sold at lower gross margins.  The average
gross profit margin for fire trucks is between 3-7%.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES.  Consolidated selling, general,
and administrative expenses increased approximately 7.7% in 1999 to
$2,176,333 from $2,019,930 in 1998.  The following table shows the breakdown
by subsidiary (and corporate expenses) as follows:

                    March 31,        March 31,
Subsidiary            1999             1998
Eaton              $ 1,234,575     $ 1,043,856
Anton                  178,629         193,543
ADCO                   353,530         344,154
SCBA                     2,324             694
ADCO South              64,441          64,986
Corporate               95,006          87,240
Conway                 141,340         173,036
Nyle Home Health           317             183
Nyer Diabetic           23,541               -
Nyer Nutritional        82,630         112,238
                   $ 2,176,333     $ 2,019,930



     The main increases came from Eaton's acquisition of two additional drug
stores.  Anton's and Conway's decrease is due to less personnel costs.

NET LOSS. In total, the Company experienced a net loss of $226,376 in 1999 as
compared to a net loss of $347,693 in 1998.  The Company sustained a loss
from continuing operations before taxes of $226,376 in 1999 as compared to a
loss of $217,758 in 1998.










FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC.   000-20175       MARCH 31, 1999

                  NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

       MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE FIRST QUARTER RESULTS

  Results of Operations: continued,


The following table summarizes the loss from continuing operations by
subsidiary:

                     March 31,        March 31,
Subsidiary             1999             1998
Eaton               $  (47,028)      $   53,966
Anton                  (35,580)         (72,313)
ADCO                   (17,312)         (29,729)
SCBA                    (2,244)           1,728
ADCO South              12,856             (913)
Corporate                1,275           32,265
Conway                 (28,455)         (79,295)
Nyle Home Health          (317)            (183)
Nyer Diabetic          (18,982)
Nyer Nutritional       (90,589)        (123,284)
                    $ (226,376)      $ (217,758)

     The majority of the loss came from the Company's subsidiary, Nyer
Nutritional, which showed a loss of $90,589 for the first quarter of 1999 as
compared to a loss of $123,284 for the same period of 1998.  Nyer Nutritional
generated no revenues for the first quarter of 1999 and is the process of
completing its new packaging for their product line. Eaton incurred
additional overhead costs associated with its sale of a store and the
implementation of a new computer system.  ADCO's loss of $17,312 as compared
to a loss of $29,729 in 1998, can be attributed to increased sales and margin
which was partially off set by costs associated with the start up of its
respiratory division in February of 1999 which had minimal sales to offset
the additional overhead.  Corporate's reduced net income of $1,275 as
compared to a net income of $32,265 in 1998, is attributable to increased
overhead for public relations and the Company had less interest income for
the first quarter of 1999 as compared to 1998.  ADCO South's net income was
the result of increased gross profit margins.  ADCO South also had minimal
equipment sales for the first quarter of 1999 as compared to 1998.  Anton and
Conway's reduction in their losses is due to less personnel costs.  Nyer
Nutritional's decrease in overhead was due to less selling and show expenses
for the first quarter of 1999 as compared to 1998's first quarter.

     The Company currently owns 739,216 shares (or 31.5%) of the outstanding
common stock of Vectors.

     In December 1998, the Company wrote down its investment in Vectors to
zero due to significant uncertainties regarding the Company's ability to
recover its investment.


FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC.   000-20175       MARCH 31, 1999

                  NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

       MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE FIRST QUARTER RESULTS

Results of Operations: continued,


    Net interest expense as a percentage of sales was less than 1% in the
first three months of 1999 and 1998, respectively.

Liquidity and Capital Resources

     In January 1999, the Company sold certain assets of a pharmacy
for cash.

     During the first quarter of 1999, the Company's pharmacy chain
borrowed on its line of credit in the amount of $200,000.  The interest
rate is prime which was 7.75% as of May 21, 1999.

     The Company anticipates at current cash levels is adequate to fund the
operating needs and potential acquisitions for the foreseeable future.

Year 2000

    IMPACT OF YEAR 2000 - Computer Systems Compliance

     The "Year 2000 Issue" is the result of the way computer
systems and programs define calendar dates; they could fail or make
miscalculations due to interpreting a date including "00" to mean
the year 1900, not year 2000.  Some computer programs were written
using two digits rather than four to define the appropriate year.
This could result in a system failure or miscalculations causing
disruptions in normal business activities.

     The Company has substantially analyzed its computer systems,
including embedded chip technology, to determine the potential
technical and economic impact of the "Year 2000 Issue" on the
Company's systems and business operations.  In the last two
years, the Company has upgraded its major computer systems and
programs.  To date, the Company has identified only one of its
subsidiaries which will have to replace its computer system in
order to be Year 2000 compliant.  The Company estimates this cost
will be no greater than $15,000.

     The Company is requesting assurances from its outside
suppliers which it relies on for inventory and services and its
customers (which includes 3rd party insurance companies), that
they are Year 2000 Compliant.




FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC.   000-20175       MARCH 31, 1999
                  NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

       MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE FIRST QUARTER RESULTS

Liquidity and Capital Resources, continued


     The Company does not expect that the costs of addressing the
Year 2000 issues (which are in the Company's control) will have a
material effect on their future operating results or financial
position.  The Company's management believes its in-house risks, as
associated with the Y2K problems, are minimal.  The Company has
limited or no control over their outside suppliers and its
customers Y2K problems.  Any failure of these parties could have
a material adverse effect on continued uninterrupted business
operations of the Company.

     At this time, the Company is in the process of developing a
contingency plan for its systems that are not Year 2000 compliant
and intends to have it in place by late second quarter of 1999.

FORWARD-LOOKING STATEMENTS

The statements made above relating to: (1) the anticipated costs to
the Company of complying with the Year 2000 conversion, (2) the
anticipated future impact as a result of outside suppliers not
being Year 2000 compliant on a timely basis are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
The results anticipated by any or all of the forward-looking
statements may not occur.

Quarter Ended March 31, 1998 as compared to Quarter Ended March 31, 1997.

     Total revenues for the first quarter of 1998 increased 16% over the
first quarter of 1997 to $7,899,806, representing an increase of $1,083,562.

The following table shows revenues of the Company's principal subsidiaries:

                     March 31,        March 31,
Subsidiary             1998             1997    % increase (decrease)
Eaton               $5,023,245      $4,028,499        24.7%
Anton                  741,013         554,102        33.7
ADCO                 1,298,842       1,325,294        (2.0)
SCBA                     8,278          16,177       (48.8)
ADCO South             281,334         263,099         7.0
Conway                 547,094         629,073       (13.0)
                    $7,899,806      $6,816,244





FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC.  000-20175        MARCH 31, 1999

                 NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

  Results of Operations: continued,

     The major reason for this increase in revenues was due to the Company's
pharmacy chain, Eaton.  Eaton acquired two pharmacies in June and September
of 1997 and one in March 1998.  This contributed to the increase in revenues
over the first quarter of 1997.  Anton's sales increased due to the opening
of a new location in New Hampshire in the middle of the first quarter of
1997, moved and expanded its Massachusetts division and the hiring of a
full-time salesman in New York in May 1997.  ADCO's sales decreased due to
the lower than expected government and equipment sales.

     The Company's overall gross margins were approximately 21.6% in 1998 as
compared 21.4% for the first quarter of 1997.


The following is a table of gross margins of the Company's principal
subsidiaries for the first quarter of 1998 and 1997:

               March 31,        March 31,
Subsidiary        1998             1997
Eaton             21.8%            21.1%
Anton             14.6             15.6
ADCO              24.6             25.1
SCBA              61.6             86.2
ADCO South        24.4             30.3
Conway            14.5             14.8

     Eaton's gross margins increased due to increased purchasing power with
the addition of two pharmacies.  Anton's gross margins decreased due to a
fire truck sale in the first quarter of 1998 as compared to $0 in 1997.
Fire truck sales have lower margins than other products sold by Anton.
ADCO South's gross margins decreased due to increased equipment sales
which have lower margins.

     Selling, general, and administrative expenses increased approximately
16% in 1998 to $2,019,930 from $1,751,827 in 1997.  The following table
shows the breakdown by subsidiary (and corporate expenses) as follows:

                    March 31,        March 31,
Subsidiary            1998             1997
Eaton              $ 1,043,856     $   796,804
Anton                  193,543         154,983
ADCO                   344,154         321,794
SCBA                       694           1,339
ADCO South              64,986          75,753
Corporate               87,240         129,154
Conway                 173,036         169,670
Nyle Home Health           183             682
Nyer Nutritional       112,238         101,648
                   $ 2,019,930     $ 1,751,827



FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC.   000-20175       MARCH 31, 1999

                  NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

       MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE FIRST QUARTER RESULTS

  Results of Operations: continued,

     The main increases came from Eaton's acquisition of two additional drug
stores and Anton's expansion in New Hampshire, Massachusetts, and New York.

     In total, the Company experienced a net loss of $347,693 in 1998 as
compared to a net loss of $281,223 in 1997.  The Company sustained a loss
from continuing operations before taxes of $217,758 in 1998 as compared to a
loss of $131,623 in 1997.

The following table summarizes the income (loss) from operations by
subsidiary:

                     March 31,        March 31,
Subsidiary             1998             1997
Eaton               $   53,966       $   85,884
Anton                  (72,313)         (58,705)
ADCO                   (29,729)          11,160
SCBA                     1,728            8,290
ADCO South                (913)             860
Corporate               32,265          (28,186)
Conway                 (79,295)         (65,913)
Nyle Home Health          (183)            (682)
Nyer Nutritional      (123,284)         (84,331)
                    $ (217,758)      $ (131,623)

     The majority of the loss came from the Company's subsidiary, Nyer
Nutritional, which showed a loss of $123,284 for the first quarter of 1998 as
compared to a loss of $84,331 for the same period of 1997.  Nyer Nutritional
generated no revenues for the first quarter of 1998 and is still incurring
start up costs and overhead costs associated with its AMTFTM product.  Eaton
incurred new overhead costs associated with its two new two pharmacies acquired
in the second and third quarter of 1997.  ADCO's loss of $29,729 as
compared to a net income of $11,160 can be attributed to lower than expected
government and equipment sales and lower margins.  Corporate's net income of
$32,265 as compared to a net loss of $28,186 is attributable to decreased
overhead costs and increased interest income.

     The Company recognized a loss from Genetic Vectors, Inc. "(Vectors")
of $117,431 for the first quarter of 1998 as compared to a loss of $34,600
in 1997. The Company currently owns 32.9% of outstanding common stock in
Vectors but it is not involved in its management and cannot affect its
results of operations.  The Company accounts for 32.9% of Vectors loss on
their consolidated financial statements as a discontinued operation.

    Net interest expense as a percentage of sales was less than 1% in the
first three months of 1999 and 1998, respectively.



FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC.   000-20175       MARCH 31, 1999

                  NYER MEDICAL GROUP, INC. AND SUBSIDIARIES
            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)





                                   PART II




  Item 3:  Other information

    The Company is still actively seeking to acquire medical related
companies.




































FORM 10-Q/A No. 1   NYER MEDICAL GROUP, INC.   000-20175       MARCH 31, 1999

                   NYER MEDICAL GROUP, INC. AND SUBSIDIARIES



                                  SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
     Registrant has duly caused this report to be signed on its behalf by the
     undersigned thereunto duly authorized.



                                                  NYER MEDICAL GROUP, INC.


     Date:  May 26, 1999                          /s/ Samuel Nyer
                                                  Samuel Nyer,
                                                  President







     Date:  May 26, 1999                          /s/ Karen L. Wright
                                                  Karen L. Wright,
                                                  Treasurer
                                                  (Chief Financial Officer)